Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5288 USD | -7.08% | -5.72% | +3.12% |
May. 20 | Sector Update: Health Care Stocks Ease Monday Afternoon | MT |
May. 20 | Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.12% | 63.68M | B- | ||
+18.72% | 125B | B+ | ||
+14.19% | 108B | B+ | ||
-4.93% | 24.21B | B+ | ||
+3.23% | 22.78B | B | ||
-10.44% | 17.96B | A- | ||
-41.74% | 16.43B | A- | ||
-13.31% | 16.37B | B | ||
+2.44% | 13.58B | C+ | ||
+27.89% | 11.66B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ATRA Stock
- Ratings Atara Biotherapeutics, Inc.